Morepen Labs anti-allergy drug Fexofinadine gets USFDA approval

New Delhi: Morepen Laboratories Limited has received U. S. Food and drug Administration (USFDA) approval for its anti-allergy drug Fexofinadine Hydrochloride that is marketed in India under the popular brand name Allegra, among others and is the block buster drug of the innovator company Sanofi Aventis, France.

Fexofinadine is most widely used, second generation antihistamine drug for the treatment of allergy symptoms and hay fever.

The company has tied-up for regular supplies of Fexofinadine to one of its top US customers, with which the company has long standing relations lasting over two decades. The company has already supplied validation quantities and the regular commercial supplies would start after approval of validation batches. Fexofinadine is a very established anti-allergy drug with a market size of around 700MT and expected to give immediate impetus to company's export business.

"Morepen is the third largest exporters of this drug to the world and will move up in the ranks after this approval. The export of Fexofenadine to the highly regulated US market is expected to see multi-fold growth resulting in better profitability margins for the company. The company is having sufficient capacity to service the present demand and is also expanding capacities to become a leading player in the product in the coming years," the company said in a release.

Fexofinadine is marketed primarily in two dosage forms 120mg and 180mg and is available to buy over the counter in many countries including USA, Australia, New Zealand, and certain countries around Europe. It is also used in combination with other anti-allergy drugs like Montelukast for which Morepen has got the largest manufacturing capacity in the world and is already approved in US market.

Mr. Sushil Suri, Chairman and Managing Director stated, "Approval of anti-allergy drug Fexofinadine (Allegra) by USFDA is an important milestone in the company's therapeutic journey since it consolidates Morepen's position in the anti-allergy market with already having USFDA approval for three lead products Loratadine, Desloratadine and Montelukast. It also cements our long-standing relations with our prime customers who have worked with us for two decades and shows their confidence in company's product quality and delivery"

This approval of Fexofenad

ine is the 5th product approved by USFDA at Morepen facilities based at Baddi, in the Solan district of State of Himachal Pradesh. 

Read also: Morepen Labs forms new subsidiary for medical devices